Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy
Yuanying Qian, Weikang Yan, Fan Xu, Yali Liu, Fabao Chen, Yue Lu, Zihan Zhang, Ao Gu, Ruobing Yu, Zhen Fang, Yang Yu, Maolan Li, Longxing Cao, Yingbin Liu, Yongning He
This paper modifies Nab-paclitaxel with receptor binders to improve tumor targeting and reduce toxicity, showing enhanced efficacy in cancer cells and xenograft models.
Journal of Controlled Release · Sep 15, 2026Peer-reviewedCancer Biology